Gut microbes play a key role in our immune systems and health - and transplanting faecal matter from one person to another is increasingly being used to control severe life-threatening infections like recurrent Clostridium difficile that kill thousands of people annually.
The procedure involves introducing a liquidised stool (or frozen microbes) from a healthy donor to the bowel of a patient to re-colonise their gut with healthy bacteria, which are often destroyed after prolonged antibiotic treatment.
A recent trial was stopped early because of the overwhelming superiority of faecal transplantation, with 90 per cent success rate compared with 26 per cent for powerful antibiotics, researchers said.
So far, after over 7,000 transplants, few adverse effects are being reported, and despite early fears, transplants even seem relatively safe in elderly patients or those with an impaired immune system, said Professor Tim Spector from King's College London and Professor Rob Knight from the University of California San Diego.
While "it is clearly better than further antibiotics for treating conditions like C difficile", the use of faecal transplantation is being increasingly tested in other common conditions, including obesity, diabetes, irritable bowel syndrome, colitis and many others.
However, claims that faecal transplantation could be a cure-all for many diseases, "are probably too optimistic," said Spector and Knight.
"These possible risks suggest that faecal transplantation, although an exciting new tool, should be carefully monitored and refined to include most of the key beneficial microbes," experts said.
"We urgently need more expertise and centres, proper screening of donors, and good long term trials and monitoring procedures in order to provide sensible advice," they said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
